FDA Approves Allergic Conjunctivitis Treatment Zerviate

Article

The ocular itching treatment is an ocular formulation of cetirizine.

The U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Zerviate, a treatment for ocular itching associated with allergic conjunctivitis.

Zerviate (cetirizine ophthalmic solution .24%) is the first topical ocular formulation of Nicox’s antihistamine cetirizine. The new treatment underwent 3 randomized, double-masked, placebo-controlled trials to prove its efficacy prior to FDA approval.

The results of the clinical conjunctival antigen challenge trials measured the treatment’s efficacy in patients with histories of allergic conjunctivitis. In 2 of these trials, Zerviate provided less ocular itching compared to vehicle at 15-minute and 8-hour markers after treatment.

About 1-7% of patients treated with either Zerviate or vehicle in clinical trials reported adverse reactions such as hyperemia, instillation site paint, and reduction in visual acuity.

Cetirzine, the active ingredient in Zyrtec, binds competitively to histamine receptor sites to reduce swelling, itching, and vasodilation. The treatment will be recommended at a dose of one drop in each affected twice daily, approximately 8 hours apart.

Partnering discussions on federal commercialization rights are currently underway for Zerviate. Due to its NDA approval prior to December of this year, a milestone payment in Nicox shares equal to $6.8 million will be triggered.

Nicox executives lauded the “milestone approval” on Wednesday.

“Today, the approval of ZERVIATE is a testament to our team’s expertise and unwavering commitment to bringing new ophthalmic treatment options to patients,” Michael Bergamini, Chief Scientific Officer and Executive Vice President of Nicox, said. “We’d like to thank the exceptional team that has worked on this project, both internally and externally.”

Related Coverage:

FDA Clears Generic Version of Strattera for ADHD Treatment

FDA Approves New Once-Daily HIV Treatment

Resveratrol-based Nutraceutical Improved Dark Adaptation in Patients with Vision Loss from AMD

Recent Videos
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
A panel of 3 experts on dry eye
© 2024 MJH Life Sciences

All rights reserved.